About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.
The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.
In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.
The objective of the line is to evaluate the added value of the information provided by quantitative MR techniques, mainly T1 and T2 relaxometry, as well as chemical exchange saturation transfer imaging (CEST) to the study of neurological and neuro-oncological diseases.
IP: Fco. Javier Aymerich Martínez, Alex Rovira Cañellas, Cristina Auger Acosta
The goal would be to assess the impact of diabetes on brain morphology, integrity and function through the advanced analysis of magnetic resonance images.
IP: Deborah Pareto Onghena, Alex Rovira Cañellas
The goal would be to assess the feasibility and the impact of new magnetic resonance sequences and image analysis tools in the characterization of patients with migraine.
The aim of the line is to evaluate the usefulness of MRI in the study of pituitary tumors, diagnosis and follow-up. The study focuses on the radiological characteristics of tumors that can predict their prognosis. Advances in neuroimaging and behavior of pituitary tumors specifically of macroadenomas are also evaluated, focusing on the radiological characteristics and their potential use with genetic and molecular markers, radiomic ACROFAST project which is a multicenter project.
IP: Silvana Isabel Sarria Estrada
IP: Alex Rovira Cañellas Collaborators: Deborah Pareto Onghena Funding agency: Fundació Institut de Recerca HUVH Funding: 160000 Reference: ROVIRA/RISE/2024 Duration: 15/11/2024 - 14/11/2028
IP: Carmen Tur Gomez Collaborators: Enrique Rodríguez Zafra, Elena Huerga Núñez, Jordina Beltran Valles Funding agency: Instituto de Salud Carlos III Funding: 152500 Reference: PI24/01277 Duration: 01/01/2025 - 31/12/2027
IP: Elena Fonseca Hernandez Collaborators: Manuel Toledo Argany, Laura Castillo Ribelles, Enric Bellido Castillo, Noelia Díaz Troyano, Samuel López Maza, Manuel Quintana Luque, Silvana Isabel Sarria Estrada Funding agency: Instituto de Salud Carlos III Funding: 196250 Reference: PI24/00862 Duration: 01/01/2025 - 31/12/2027
IP: Alvaro Cobo Calvo Collaborators: Cristina Auger Acosta, Miguel Angel Robles Sanchez, Elisa Marín Ordovás, Mireia Castillo Juarez, Luca Bollo Funding agency: Instituto de Salud Carlos III Funding: 201875 Reference: PI24/00859 Duration: 01/01/2025 - 31/12/2027
PhD student: Silvana Isabel Sarria Estrada Director/s: Jordi Giralt López de Sagred University: Universidad Autònoma de Barcelona Year: 2021
Dr. Xavier Montalban, Dr. Álex Rovira, Dr. Mar Tintoré and Dr. Jaume Sastre Garriga have been recognised in the listing.
Her nomination means that she will represent UPF in the national competition held annually.
The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.
Magnetic Resonance image analysis
